Pulse BiosciencesPLSE
About: Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
Employees: 56
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
120% more call options, than puts
Call options by funds: $3.34M | Put options by funds: $1.52M
81% more capital invested
Capital invested by funds: $54.5M [Q2] → $98.4M (+$43.9M) [Q3]
26% more funds holding
Funds holding: 57 [Q2] → 72 (+15) [Q3]
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
0.35% more ownership
Funds ownership: 8.82% [Q2] → 9.17% (+0.35%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for PLSE.